Abiopharma

KLOTHO NEUROSCIENCES, INC. (GRMLW)

Symbol	GRMLW
Name	KLOTHO NEUROSCIENCES, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Biological Products (No Diagnostic Substances)
Address	1300 SOUTH BOULEVARD,SUITE D, CHARLOTTE, North Carolina, 28203, United States
Telephone	+1 833 931-6330
Fax	—
Email	—
Website	https://www.klothoneuro.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001907223
Description	Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimers and Parkinsons Disease, multiple sclerosis and rare neurodegenerative diseases. The companys current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. Additional info from NASDAQ: Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimers and Parkinsons Disease, multiple sclerosis and rare neurodegenerative diseases. The companys current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject.

2026-09-02 13:15

Rare Earths Could Become the Mining Sectors Next Billion-Dollar Opportunity

2026-09-02 13:00

Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval

2026-08-27 15:30

Greenland Mines Set to Close Sarfartoq Rare Earths Acquisition by Sept. 1, 2026

2026-08-27 11:50

New Form 424B5 - Greenland Mines Ltd Filed: 2026-08-27 AccNo: 0001213900-26-094216 Size: 393 KB

2026-08-26 12:00

Greenland Mines Announces Pricing of $20 Million Public Offering

2026-08-25 18:22

New Form 424B5 - Greenland Mines Ltd Filed: 2026-08-25 AccNo: 0001213900-26-093597 Size: 390 KB

2026-08-25 13:59

LeBlanc Jeff 🟢 acquired 14.0K shares of Greenland Mines Ltd (GRML) at $9.72 Transaction Date: Aug 25, 2026 | Filing ID: 093307

2026-08-25 13:30

Greenland Mines Sarfartoq Nd-Pr Rare Earth Project Valued Up to US$2.05 Billion With Pre-Tax IRR of 118.6% and Significant Additional Upside Potential

2026-08-25 04:01

Greenland Mines Sarfartoq Nd-Pr Rare Earth Project Valued Up to US$2.05 Billion With Pre-Tax IRR of 118.6% and Significant Additional Upside Potential

2026-08-24 21:10

(99% Neutral) KLOTHO NEUROSCIENCES, INC. (GRMLW) Announces Business Combination

No clinical trials found for this company.

No clinical products found for this company.